Drug firm Wyeth Ltd today reported 28.31 per cent increase in its standalone net profit to Rs 28.46 crore for the quarter ended June 30, 2014-15, mainly on account of robust sales.
The company had posted net profit of Rs 22.18 crore for the corresponding period of the previous financial year, Wyeth said in a filing to the BSE.
Standalone net sales of the company also rose in the April-June quarter to Rs 191.18 crore, from Rs 164.30 crore for the same period year ago.
Wyeth Ltd is a group company of US-based pharma major Pfizer Inc and focuses in the areas of antibiotics, vaccines, corticosteroids and women’s health.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.